IMVT vs PRU · $2.90B cap vs rev $31.19B
Immunovant Inc (IMVT) versus PRU (PRU) — a side-by-side from cached financials, not a winner call.
Immunovant Inc (IMVT) is a biotechnology company listed on US.
PRU (PRU) common stock.
IMVT does not have a complete income-statement cache yet.
Latest reported PRU revenue for 2026-06-30 was $31.19B. Net income was $1.58B. PRU currently screens at market cap $0.
IMVT currently screens at market cap $2.90B. PRU currently screens at market cap $0.
Not investment advice. Open the IMVT and PRU stock pages for the full models.
Not investment advice.